INS and type 2 diabetes mellitus: For instance, a recent study comparing tirzepatide to preprandial insulin lispro in patients with T2D treated with insulin glargine (mean dose 46 U/day) demonstrated that patients receiving tirzepatide (15 mg dose) ended the study with an average glargine dose of only 8 U/day (versus 112 U/day in the lispro group).